{"id":"NCT00053846","sponsor":"University of Rochester","briefTitle":"Buspirone in Reducing Shortness of Breath in Patients With Cancer","officialTitle":"Buspirone in Reducing Shortness of Breath in Patients With Cancer","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2002-11","primaryCompletion":"2010-11","completion":"2011-01","firstPosted":"2003-02-06","resultsPosted":"2015-03-20","lastUpdate":"2015-11-24"},"enrollment":432,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Dyspnea","Pulmonary Complications","Unspecified Adult Solid Tumor, Protocol Specific"],"interventions":[{"type":"DRUG","name":"buspirone hydrochloride","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"buspirone hydrochloride","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy.\n\nPURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer.","primaryOutcome":{"measure":"Dyspnea as Measured by Oxygen Cost Diagram (OCD)","timeFrame":"28 days after beginning study drug or placebo","effectByArm":[{"arm":"Buspirone Hydrochloride","deltaMin":8.98,"sd":2.85},{"arm":"Placebo","deltaMin":9.32,"sd":2.62}],"pValues":[{"comp":"OG000 vs OG001","p":"0.080"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":213},"commonTop":["Dyspnea","Dizziness, confusion; insomnia","Nausea and vomitting","Esophagitis","Shakes and tremors"]}}